EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial

Patrick Charles Stone iD, Ollie Minton, Alison Richardson iD, Peter Buckle iD, Zinat E Enayat, Louise Marston iD, Nick Freemantle

Journal of Clinical Oncology · 17.05.2024

DOI: 10.1200/jco.23.02639 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, online erschienen am 17.05.2024. Verfasst von Patrick Charles Stone und 6 weiteren Autor:innen. Beteiligte Einrichtung: Marie Curie Palliative Care Research Department, Division of Psychiatry, University College London (UCL), London, United Kingdom. Hauptthemen laut MEDLINE: Methylphenidate, Fatigue, Neoplasms, Quality of Life. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To compare effects and side effects of 6 weeks of individually dose-titrated methylphenidate or placebo on fatigue in palliative care patients with advanced cancer. METHODS This is a randomized, double-blind, placebo-controlled, multicenter trial. Eligible patients had advanced incurable cancer and fatigue >3/10. Principal exclusions were hypertension; psychiatric, cardiovascular, cerebrovascular, renal, liver, or blood disorders; substance dependency; and epilepsy. Patients were randomly assigned 1:1 methylphenidate or placebo starting at 5 mg twice daily. Dose of methylphenidate/placebo was titrated once per week, over 6 weeks, up to a maximum of 20 mg three times daily. Trial ended at 10 weeks. Primary outcome was the difference in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) scores between groups at 6 ± 2 weeks. Secondary outcomes included adverse effects, quality of life, and mood. RESULTS One hundred sixty-two patients (73 men; mean, 65.8; standard deviation [SD], 10.3 years) were randomly assigned, and three were excluded from analysis. Seventy-seven were allocated placebo (baseline FACIT-F = 22 [SD, 10]); 82 were allocated methylphenidate (FACIT-F = 20 [SD, 9]). After 6 ± 2 weeks, FACIT-F scores were 1.97 points (95% CI, –0.95 to 4.90; P = .186) higher (better) on methylphenidate than placebo. Across 10 weeks of the study, FACIT-F was nominally higher in the methylphenidate group versus placebo (Diff, 2.20 [95% CI, 0.39 to 4.01]), but this did not reach the minimally clinically important difference (5-points). At 6 weeks, there were no differences between groups in quality-of-life or symptom domains except for depression scores (nominally reduced in the methylphenidate group: Diff, –1.35 [95% CI, –2.41 to –0.30]). There were no differences in mortality or serious adverse events. CONCLUSION After 6 ± 2 weeks of treatment, methylphenidate was not superior to placebo for treating fatigue in advanced cancer. Methylphenidate was safe and well-tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethylphenidateFatigueNeoplasmsQuality of LifeCentral Nervous System StimulantsHumansMaleDouble-Blind MethodFemaleAgedMiddle AgedTreatment OutcomePalliative Care

Substanzen

MethylphenidateCentral Nervous System Stimulants

Autor:innen und Institutionen

  • Marie Curie Palliative Care Research Department, Division of Psychiatry, University College London (UCL), London, United Kingdom.
  • University Hospitals Sussex NHS Foundation Trust, Worthing Hospital, Lyndhurst Road, Worthing, West Sussex, United Kingdom.
  • University of Southampton & University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Southampton, United Kingdom.
  • Department of Primary Care & Population Health, Institute of Epidemiology & Health Care, Faculty of Population Health Sciences, University College London (UCL), London, United Kingdom.
  • Comprehensive Clinical Trials Unit, University College London (UCL), London, United Kingdom.

ORCID-Profile: Patrick Charles Stone, Alison Richardson, Peter Buckle, Louise Marston

Zitieren

APA

Stone, P. C., Minton, O., Richardson, A., Buckle, P., Enayat, Z. E., Marston, L., & Freemantle, N. (2024). Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02639

Vancouver

Stone PC, Minton O, Richardson A, Buckle P, Enayat ZE, Marston L, et al. Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.02639

BibTeX
@article{Stone2024,
  author = {Stone, Patrick Charles and Minton, Ollie and Richardson, Alison and Buckle, Peter and Enayat, Zinat E and Marston, Louise and Freemantle, Nick},
  title = {Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.02639}
}
Kostenlos starten →